Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (156)
ARTG (126)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)

Date

2024 (120)
2023 (16)
2022 (13)
2021 (68)
2020 (23)
2019 (11)
2018 (6)
2017 (8)
2016 (25)
2015 (9)
2012 (2)
2011 (4)
2010 (1)
2006 (3)
2002 (7)
1995 (2)

Results for "[search-keyword]"

Search

Sponsor content

318 result(s) found, displaying 61 to 70

PACLITAXIN paclitaxel 150 mg/25 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PACLITAXIN paclitaxel 100 mg/16.7 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
COPAXONE glatiramer acetate 20mg/1mL solution for injection prefilled syringe Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-ABIRATERONE abiraterone acetate 500 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-ABIRATERONE abiraterone acetate 250 mg film-coated tablet bottle pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-SUGAMMADEX sugammadex (as sodium) 200 mg/2 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-SUGAMMADEX sugammadex (as sodium) 500 mg/5 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-FINGOLIMOD fingolimod (as hydrochloride) 0.5 mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-SITAGLIPTIN sitagliptin (as malate) 50 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-SITAGLIPTIN sitagliptin (as malate) 25 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.